Organon OGN Other Operating And Nonoperating Income (Expense)
Other Operating And Nonoperating Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Organon in its filing.
Tagged under the XBRL concept ogn:OtherOperatingAndNonoperatingIncomeExpense.
The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Organon's other operating and nonoperating income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Organon's other operating and nonoperating income (expense)?
- Organon (OGN) reported other operating and nonoperating income (expense) of $96M in Q1 2026.
- How has Organon's other operating and nonoperating income (expense) changed year-over-year?
- Organon's other operating and nonoperating income (expense) increased by 900.0% year-over-year, from -$12M to $96M.
- What is the long-term trend for Organon's other operating and nonoperating income (expense)?
- Over 4 years (2021 to 2025), Organon's other operating and nonoperating income (expense) has grown at a 52.5% compound annual growth rate (CAGR), from -$22M to $119M.
- What does other operating and nonoperating income (expense) mean?
- This metric captures miscellaneous income or expenses that do not fall under core operating activities, such as gains or losses from asset disposals, litigation settlements, or non-recurring financial adjustments. It serves as a catch-all for peripheral financial events that impact the bottom line but are not indicative of the company's primary pharmaceutical business performance. Investors analyze this to isolate core operational profitability from transient or non-operational financial fluctuations.